Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.3.a.u2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2019
Dec. 31, 2018
ASSETS    
Cash $ 4,931 $ 89
Current assets    
Prepaid expenses 10,966 12,991
Total current assets 15,897 13,080
Total Assets 15,897 13,080
Accounts payable 163,097 191,714
LIABILITIES & STOCKHOLDERS' DEFICIT    
Accrued expenses 419,572 421,000
Current liabilities    
Accrued interest payable 615,885 537,118
Related party payables 1,454,375 1,423,984
Derivative liabilities 52,900
Stock subscriptions payable 2,058 1,271
Notes payable - current - related parties * Includes unamortized debt discount related to detached warrants of $28,011 and $8,074 at June 30, 2019 and December 31, 2018, respectively 752,583 697,770
Notes payable - current - non - related parties * Includes unamortized discount related to convertible notes of $44,257 and $5,920 at June 30,2019 and December 31, 2018, respectively 185,317 163,654
Total current liabilities 3,645,787 3,436,511
Total Liabilities 3,645,787 3,436,511
Preferred stock, $0.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of June 30, 2019 and December 31, 2018
Common stock, $0.00001 par value; 800,000,000 shares authorized; 152,205,625 and 109,409,930 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively 1,522 1,172
Stockholders' Deficit    
Additional paid-in capital 14,977,006 14,887,804
Accumulated deficit (18,556,562) (18,262,136)
Total Transbiotec, Inc. stockholders' deficit (3,578,020) (3,373,146)
Noncontrolling interest (51,870) (50,285)
Total Stockholders' Deficit (3,629,890) (3,423,431)
Total Liabilities and Stockholders' Deficit 15,897 13,080
Series A Convertible Preferred Stock [Member]    
Stockholders' Deficit    
Series A Convertible Preferred stock, $0.00001 par value; 3,000,000 shares authorized, 1,388,575 shares issued and outstanding as of June 30, 2019 and December 31, 2018 $ 14 $ 14